既往接种疫苗的慢性肾脏病成人黄热病中和抗体血清阳性率及滴度
这项横断面研究评估了既往接种黄热病疫苗的慢性肾脏病成人(透析或非透析)与健康人的中和抗体血清阳性率和滴度。采用微量空斑减少中和-辣根过氧化物酶试验,血清阳性 cutoff 为≥1:100。三组血清阳性率无统计学显著差异:非透析CKD 100%、透析CKD 96%、健康对照100%;几何平均滴度分别为818.5、683.0和665.5(p=0.289)。
要点
- 非透析CKD、透析CKD和健康对照的血清阳性率分别为100%、96%和100%。
- 三组几何平均滴度分别为818.5、683.0和665.5,差异无统计学显著(p=0.289)。
- 研究为横断面设计,样本量153例,既往接种黄热病疫苗的中位时间各组不同。
核心结论
- 既往接种黄热病疫苗的慢性肾脏病成人(无论是否透析)与健康人相比,黄热病中和抗体血清阳性率和滴度均无统计学显著差异。
研究设计与样本
- 横断面研究,纳入153名既往接种黄热病疫苗的成人,包括46例非透析慢性肾脏病、50例透析慢性肾脏病和57名健康成人;采用微量空斑减少中和-辣根过氧化物酶试验检测中和抗体,血清阳性 cutoff 为≥1:100。
主要发现
- 非透析CKD组、透析CKD组和健康对照组的黄热病血清阳性率分别为100%、96%和100%,组间无统计学显著差异。
- 非透析CKD组、透析CKD组和健康对照组的黄热病中和抗体几何平均滴度分别为818.5、683.0和665.5,组间比较p=0.289。
- 三组中位年龄分别为58.3岁、55岁和52.2岁,距黄热病疫苗接种的中位时间分别为22.3个月、18.5个月和48.3个月。
关键数值与推荐
- 血清阳性定义为微量空斑减少中和试验50%中和滴度(μPRN50)≥1:100。
- 非透析CKD组血清阳性率为100%(46例中),透析CKD组为96%(50例中),健康对照组为100%(57例中)。
- 几何平均滴度:非透析CKD组818.5,透析CKD组683.0,健康对照组665.5,组间p=0.289。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies on yellow fever vaccine (YF) in chronic kidney disease (CKD) patients are scarce. This cross-sectional study aimed to evaluate YF neutralizing antibody seroprevalence and titers in previously vaccinated adults with CKD, on dialysis (D-CKD) or not (ND-CKD), compared to healthy persons. The micro Plaque Reduction Neutralization-Horseradish Peroxidase (μPRN-HP) test was used. Antibody titers were expressed as the reciprocal of the highest dilution that neutralized the challenge virus by 50 % (μPRN50). Seropositivity cut-off was set at ≥ 1:100. We included 153 participants: 46 ND-CKD, 50 D-CKD and 57 healthy adults. Median ages were 58.3, 55 and 52.2 years, respectively. Median time since YF vaccination was 22.3, 18.5 and 48.3 months respectively. There were no statistically significant differences in YF seroprevalence and neutralizing antibodies titers among groups: 100 % of ND-CKD; 96 % of D-CKD and 100 % of healthy participants were seropositive. Geometric mean titers (GMT) were 818.5, 683.0 and 665.5, respectively (p = 0.289).
引用
- Cristina Martini Rodrigues C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, et al. Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease. Vaccine. 2024. PMID: 38514353. doi:10.1016/j.vaccine.2024.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。